Evidence map›Paper›PMID 36128875›Full record

ArticleJournal of enzyme inhibition and medicinal chemistry2022

Design, synthesis and evaluation of novel small molecules acting as Keap1-Nrf2 protein-protein interaction inhibitors.

Yunfeng Sun, Lulu Zheng, Bo Yang, Shuyu Ge, Qiang Li, Mingwan Zhang, Shenghui Shen, Yin Ying

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of enzyme inhibition and medicinal chemistry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.8field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 9 citations in OpenAlex.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Yunfeng SunDepartment of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
Lulu ZhengDepartment of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
Bo YangDepartment of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
Shuyu GeDepartment of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
Qiang LiDepartment of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
Mingwan ZhangDepartment of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
Shenghui ShenDepartment of Cardiology, Tongde Hospital of Zhejiang Province, Hangzhou, Zhejiang, China.
Yin YingDepartment of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, Zhejiang, China.
Tongde Hospital of Zhejiang Province · CNSichuan Academy of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Direct interference with Kelch-like ECH-associated protein 1 (Keap1)-Nrf2 protein-protein interaction (PPI) has recently been introduced as an attractive approach to control life-threatening diseases like myocarditis. The present study aimed to investigate the potential application in myocarditis of a series of novel non-naphthalene derivatives as potential Keap1-Nrf2 PPI inhibitors. Our results indicated that the optimal compound

Indexed as

MyocarditisNF-E2-Related Factor 2HumansKelch-Like ECH-Associated Protein 1LipopolysaccharidesReactive Oxygen SpeciesRNA, MessengerKEAP1 protein, humanKelch-Like ECH-Associated Protein 1LipopolysaccharidesNF-E2-Related Factor 2Reactive Oxygen SpeciesRNA, Messengerdrug designinflammatory responseKeap1-Nrf2 PPI inhibitormyocarditisoxidative stresssynthesis

Identifiers

PMID36128875
PMCPMC9518255
OpenAlexW4296700206

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.